Marijuana - Public Weed Stocks & Analysis

[PharmaGreen007]

Dr. Sazzad Hossain, Ph.D., M.Sc.
Chief Scientific Officer
Dr. Hossain has more than 20 years of academic and industrial experience in new drug discovery, natural health product development. He was Group Leader and Senior Scientist at Biotechnology Research Institute of National Research Council Canada, Government of Canada's prime biotechnology research organization where he set up pharmacology laboratory to evaluate safety and efficacy of new drugs under development in the areas of cancer, cardiovascular and ocular diseases. Prior to joining the National Research Council Canada, he was at Xenon Pharmaceuticals in Vancouver, B.C, where was Associate Director of Pharmacology and led pharmacology teams targeting pain, inflammation and cardiovascular diseases. Dr. Hossain received his PhD in Biology from Moscow State Academy of Veterinary Medicine & Biotechnology and received post-doctoral training in the Department of Nutritional Science and Department of Medical Genetics of University of British Columbia. He was associate professor of pharmacology at Federal University of Minas Gerais, Brazil between 1988 -1996. He is the author of more than 40 peer-reviewed papers, primarily in the pharmacology, genetics and nutritional sciences.


Platform Technology

Our proprietary Intelligent Cannabinoid Drug Design Platform IDP allows bioinformatics tools to identify individual chemical compounds from cannabis & non-cannabis plants which can be targeted to develop therapies for specific diseases and conditions.

The Advantages of our IDP:
•Generates new therapies based on scientifically proven genomics and metabolomics both quickly and effectively.
•Therapies have an accelerated pathway for drug development and commercialization: ~3-5 yrs. vs. traditional 10-15 yrs.
•Network Based Approach of our IDP allows us to Reposition Drugs Based on Common Disease Mechanism & Generate New IP.

CTI-085

Is a topical formulation containing a proprietary compound of cannabinoids and non-cannabis based active ingredients for the treatment of Glaucoma. Cannabis Technologies has identified our lead composition (CTI 085) through 12 months of discovery and preclinical studies that showed efficacy in lowering intraocular pressure (IOP) in animal models. Cannabinoids have IOP lowering effects, thus, they have therapeutic potential in the treatment of glaucoma. Our objective for this therapy was to develop a safer; cannabis based topical anti-glaucoma formulation without systemic side effects.

CTI-091

Is a proprietary mixture of cannabinoids and non-cannabis based active ingredients designed for the relief of joint pain and swelling associated with arthritis and joint disease. Preliminary laboratory studies showed CTI-091 suppresses the human macrophage interleukin-6, a major biomarker of inflammation. We are currently developing an innovative new delivery system to enhance retention and absorption of the key active ingredients around the target site to relieve joint pain and swelling.